The Guide to the Expression of Uncertainty in Measurement (GUM) provides instructions for constructing uncertainty intervals for a measurement. This method is usually reserved for reference materials, but GUM has been recently proposed as a way to express uncertainty for commercial diagnostic assays. Methods: Using the official GUM standard and published applications of GUM to commercial diagnostic assays, I undertook an analysis to evaluate whether applying GUM to commercial diagnostic assays is warranted. Results: Certain important assays, such as troponin I, would not be candidates for GUM because troponin I is not a well-defined physical quantity. Unlike definitive methods, in which efforts are taken to detect and eliminate all systematic error sources, commercial assays often trade off features such as ease of use and cost with accuracy and allow systematic errors to be present as long as the overall accuracy meets the medical need goal. Laboratories are hindered in preparing GUM models because the knowledge required to specify some systematic errors is often available only to manufacturers. Some non-GUM methods to estimate uncertainty rely on observed data, which include both known and unknown sources of error. The occurrence of large, unknown errors for assays in routine use (e.g., outliers) is not unusual because diagnostic assays must be chemically specific in the presence of thousands of potentially interfering substances. There is no provision in GUM to deal with unexplained outliers, which may lead to uncertainty intervals that are not wide enough. Some clinicians assume that diagnostic assay results have little uncertainty. This situation may be made worse by including an uncertainty interval, which implies certification. Conclusions: Evaluations for accuracy (total analytical error) based on describing the distribution of result differences between commercial assays and reference methods indicate that some assays have a few results with large differences (e.g., outliers). This leads to a wide accuracy interval (total analytical error limits). It is unlikely that GUM would be able to predict these wide intervals, especially because there is little or no provision for outlier treatment in GUM. Presenting too narrow GUM uncertainty intervals to clinicians would be misleading. The modeling used by practitioners of the GUM method is potentially useful in improving quality, but commercial diagnostic assays are not ready for GUM uncertainty statements.
analysis of calcium and glucose in human serum (3, 4 ) . Kristiansen (5 ) described how GUM applies to diagnostic assays. Here I will describe problems with the GUM method with respect to its use for routine diagnostic assays. Kallner (6 ) and the NIST web site (7 ) provide excellent descriptions of the GUM method. Grabe (8 ) has critiqued the GUM method. To briefly summarize the GUM approach, GUM considers random error and systematic error as the two possible sources of measurement error. The uncertainty of a measurement result stems from uncertainty attributable to random effects and from imperfect correction of systematic effects.
For the purpose of evaluating uncertainty components, GUM groups uncertainty components into two categories: types "A" and "B". Type A uncertainties are obtained from probability density functions derived from observed frequency distributions, whereas type B uncertainties are obtained from assumed probability density functions. The standard uncertainty of a measurement result, when that result is estimated from the values of other quantities, is called the combined uncertainty and follows the law of propagation of uncertainty. Finally, the combined uncertainty can be multiplied by a coverage factor, k, to yield an expanded uncertainty, which provides an interval about the result of a measurement expected to contain a large fraction of the values. This interval is similar in concept to accuracy or total analytical error (9 ) .
Differences between Commercial Diagnostic Assays and Processes Used for GUM
The GUM guideline states: "This Guide is primarily concerned with the expression of uncertainty in the measurement of a well-defined physical quantity-the measurand-that can be characterized by an essentially unique value". Unfortunately, this excludes some important diagnostic assays. As an example, troponin I assays can routinely differ by as much as 100-fold from one another (10 ) . This has been ascribed to different epitopes in different commercial assays; hence troponin I is not a well-defined physical quantity as defined by GUM. The GUM guideline also states: "It is assumed that the result of a measurement has been corrected for all recognized significant systematic effects and that every effort has been made to identify such effects". This amount of effort is commonly carried out for a reference material, whose value has been determined with a definitive method. Tietz (11 ) described the differences among definitive, reference, and field assays for clinical chemistry assays.
Commercial assays (field assays in Tietz's terminology) are developed differently than are definitive assays because of different market needs. Commercial assays often emphasize ease of use and low cost, whereas definitive assays focus on attaining the best accuracy possible. For commercial assays, lower accuracy is justified because of affordability and other features (such as ease of use) and the fact that the lower accuracy is still often within stated goals.
As an example, home-use glucose assays serve an important medical need but have not minimized systematic errors to the same extent as the definitive method for assaying glucose. A patient sample contains, in addition to the analyte of interest, thousands of other chemical substances, some of which might interfere in a commercial assay. Although manufacturers attempt to investigate and minimize the effects of interfering substances, reports of assays that nonetheless suffer from these effects are not all that uncommon (12 ) . These reports typically provide an explanation of the root cause of the error, which is often an uncorrected systematic error that has caused clinician concern if not actual harm to the patient.
Size of Systematic Errors
GUM states that systematic errors can be reduced if the systematic error is "significant in size relative to the required accuracy of the measurement". This of course requires a goal for the accuracy of a measurement. Because there can be many systematic and random error sources, one must create a mathematical model that details how each error source contributes to the overall accuracy of a measurement (the combined uncertainty), create goals for each error source, and assess the magnitude of each source. There are some examples of this (13 ) , which in essence is what GUM is all about.
Field assays typically have lower accuracy requirements (combined uncertainty) than definitive methods. For example, a draft International Organization for Standardization (ISO) glucose document states: "Ninety-five percent (95%) of the individual glucose results shall fall within Ϯ 0.83 mmol/L (15 mg/dL) of the results of the manufacturer's measurement procedure at glucose concentrations Յ 4.2 mmol/L (75 mg/dL) and within Ϯ20% at glucose concentrations Ͼ4.2 mmol/L (75 mg/dL)" (14 ) . It would seem to go against the grain of clinical chemists, however, to ignore as insignificant errors that are detected but fall below these limits. Thus a 10% nonlinearity in a glucose assay would likely be detectable and could be corrected even if a mathematical model could show that the 10% nonlinearity would not lead to failing the combined uncertainty goal. The reason is that laboratorians almost always wish to improve quality; the medically acceptable limits for combined uncertainty do not represent a dichotomous limit where on one side there will be high quality and on the other side poor quality. Rather, there is a continuum of quality so that laboratorians are always trying to improve the combined uncertainty, given economic constraints (15 ) .
Treatment of Systematic Errors
The GUM approach has three ways to treat recognized significant systematic error. To illustrate this, consider a sodium assay with respect to the error source: calibrator lot value assignment error. Each time the calibrator lot is Clinical Chemistry 49, No. 11, 2003 changed, there is a possible fixed bias that lasts until the next calibrator lot change. Whether this bias is observed depends on the laboratory procedure for evaluating calibrator lot changes and on the laboratory's routine qualitycontrol procedure.
Method 1: The laboratory detects a significant bias in a new calibrator lot and adjusts values to minimize the bias.
Method 2: The laboratory has a certificate from the manufacturer and uses the uncertainty statement from the manufacturer to calculate a standard uncertainty attributable to calibrator error.
Method 3: The laboratory evaluates multiple calibrator lots in an experiment that calculates the standard uncertainty of the calibrator through an ANOVA model. Typically, this evaluation would be done once as part of an evaluation of the candidate assay.
Assume that method 2 or method 3 has been followed for all systematic error sources (e.g., instrument, reagent, calibrator, operator), and an expanded uncertainty statement has been provided. Laboratorians get into a quandary here. If a laboratorian finds a systematic bias, then he or she should eliminate it. However, ensuring that "every effort has been made to identify such (systematic) effects" might mean that each change in every potential systematic error source should be evaluated. This is beyond the scope of most laboratories, although in principle it is desirable. The GUM statement is ultimately what all laboratorians want to achieve. One wants to know the sodium value and its uncertainty independently of any factors. This is particularly important as people travel throughout the healthcare system.
Lack of Knowledge in Laboratory Error Modeling in GUM
To model errors, Kristiansen (5 ) suggests the use of cause-and-effect diagrams. Many of the effects described in a cause-and-effect diagram prepared by a laboratory, although conceptually correct, will suffer because information known to a manufacturer is usually unavailable to the laboratory. As one example, consider the error in the recalibration of Po 2 for a blood gas analyzer. It is unlikely for the laboratory to know the possible transformations in use in calibration equations. In a typical case, Po 2 responses from multiple standards have been previously fit to a quadratic, quadratic spline with one knot by the manufacturer. The transformation allows the use of two standards (e.g., which implies linearity) for routine calibration of an inherently nonlinear response (because of leaks in the analyzer). However, this also means that possible additional biases may result from errors in either the original spline fit or in drift in the responses used to estimate the spline.
There are many other algorithms that manufacturers embed in instrument software that monitor response quality in each sample and lead to either throwing out part of the response data or altogether rejecting an analyzer result. The details of these algorithms are generally unknown by laboratories, but they can cause errors if incorrect.
Of course, if manufacturers disclosed this type of information, laboratories would be able to improve the faithfulness of their models, but this type of disclosure is unlikely because manufacturers will rightly consider these quality algorithms as proprietary.
Treatment of Outliers
Clinical chemists typically estimate performance parameters using observed data. GUM uses detailed models that describe all error sources. The models are typically based on both assumptions and observed data. The GUM expanded uncertainty statement provides an interval about the result of measurement expected to contain a large fraction of the values by use of a coverage factor based on a gaussian distribution. However, distributions using observed data (i.e., empirical distributions) often exhibit nongaussian shapes.
In an example (16 ) , based on data from Miller et al. (17 ) , 100 randomly collected patient samples were assayed by a commercially available LDL-cholesterol assay and by a reference assay. A nonparametric 95% confidence interval containing at least 95% of the LDL-cholesterol differences between the commercial and reference assays ranged from Ϫ0.47 to 5.66 mmol/L (Ϫ18 to 219 mg/dL). This huge interval was caused by three outliers in the data. It is unlikely that a GUM approach would have come close to this interval. Reporting this interval with every LDL-cholesterol result is, of course, not useful. However, outliers such as those found here are not only real, albeit infrequent, but precisely the cases that contribute to incorrect medical decisions. In any evaluation, including those conforming to GUM, one should try to determine the root cause of outliers. If outliers are caused by recording mistakes, they may be discarded. However, it is possible, and more so for a laboratory than a manufacturer, that the root cause for an outlier may remain undetermined and hence uncorrected. There is no provision for this in GUM because large systematic errors must be corrected.
Unfortunately, some interpretations of GUM suggest that certain outliers may be discarded (18 ) . In the EURACHEM/CITAC guide referenced by Linko et al. (4 ) in their example using GUM, an instrument malfunction such as "an air bubble lodged in a spectrophotometer flowthrough cell" can be discarded as a spurious error. If an algorithm detects a bubble and discards the result as part of the assay routine, then this is acceptable, but if a user visually detects a bubble during an evaluation and would not be routinely performing this check, discarding this result will bias the evaluation. Krouwer (9 ) has summarized methods that directly estimate inaccuracy (total error) from observed data. Some of the methods do not require modeling at all, although one must ensure that the samples are representative and that sufficient data are collected.
Clinicians and Laboratory Error
Adding an uncertainty statement to a measurement confers an air of authority to the measurement's validity. Although the use of uncertainty intervals has been a longstanding tradition for reference materials (19 ) , it may send the wrong message to clinicians. It would appear today that even without the addition of uncertainty statements, some clinicians believe that results from laboratory assays have little or no uncertainty. Consider a case reported in the media that involved a woman with an increased human chorionic gonadotropin (hCG) (20 ) . Clinicians suspected trophoblastic carcinoma, based in part on the increased hCG result, and over several months provided chemotherapy followed by two surgical procedures: hysterectomy and partial removal of one lung. It took 45 hCG assays (all increased) and negative pathology reports before assay error was suspected. Interference by human anti-mouse antibody was confirmed as the source of the assay error; the woman had no cancer. This was not an isolated case; Rotmensch and Cole (21 ) and Cole et al. (22 ) found that in 78 cases, there were 35 instances of false-positive errors with 12 cases of unnecessary cancer therapy. A survey (12 ) of performance complaints showed that previously unknown clinically important interference errors in diagnostic assays were the most frequent error source reported. The magnitude of these errors is often well beyond a reasonable uncertainty interval.
Underestimating uncertainty is not limited to diagnostic assays. Youden (23 ) compiled 15 different estimates of the astronomical unit from scientists who estimated that quantity over the years 1895-1961. The confidence interval constructed by every scientist did not overlap the confidence interval of his predecessor.
Recommendations
The GUM uncertainty statement is what is ultimately desired for diagnostic assays. To get there, quality improvement must take place. The modeling by Kristiansen (5 ) is valuable as a means to identify and rank the importance of errors. However, until diagnostic assays are closer to the quality of definitive methods, the use of GUM uncertainty statements is not recommended.
Counterpoint The Guide to Expression of Uncertainty in Measurement Approach for
Estimating Uncertainty: An Appraisal
Jesper Kristiansen
Background: The aim of the Guide to Expression of Uncertainty in Measurement (GUM) is to harmonize the different practices for estimating and reporting uncertainty of measurement. Although there are clear advantages in having a common approach for evaluating uncertainty, application of the GUM approach to chemistry measurements is not straightforward. In the above commentary, Krouwer suggests that the GUM approach should not be applied to diagnostic assays, because (a) the quality of diagnostic assays is to low, and (b) the GUM uncertainty intervals are too narrow to predict the outliers that occasionally trouble these methods. Methods: Some of the examples presented by Krouwer are reviewed. Sodium measurements are modeled mathematically to illustrate the GUM approach to uncertainty. A standardized uncertainty evaluation process is presented.
Results:
Modeling of sodium measurements demonstrates how the GUM uncertainty interval reflects the treatment of a bias: The width of the uncertainty interval varied depending on whether a correction for a calibrator lot bias was applied, but in both cases it was consistent with the distribution of measurement results. Expanding the uncertainty interval to include outliers runs counter to the definition of uncertainty. Used appropriately, the GUM uncertainty can be helpful in detecting outliers. In standardizing the uncertainty evaluation, the importance of the analytical imprecision and traceability was emphasized. It is problematic that manufacturers of commercial assays rarely inform about the uncertainty of the values assigned to the calibrators. As demonstrated by an example, external quality-assurance data may be used to estimate this uncertainty.
Conclusions:
The GUM uncertainty should be applied to measurements in laboratory medicine because it may actually support the forces that drive the work on improving the quality of measurement procedures. However, it is important that the GUM approach is made more manageable by standardizing the uncertainty evaluation procedure as much as possible. It is essential to focus on the traceability and uncertainty of calibrators and reagents supplied by manufacturers of assays. Information about uncertainty is necessary in the evaluation of the uncertainty associated with manufacturers' measurement procedures, and in general it may force manufacturers to increase their efforts in improving the metrologic and analytical quality of their products.
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In the above commentary Krouwer (1 ) criticizes the so-called Guide to Expression of Uncertainty in Measurement (GUM) 1 uncertainty and concludes that although GUM uncertainty may be suitable for values assigned to reference materials, the application of the GUM approach to commercial diagnostic assays is not warranted. By dismissing GUM uncertainty, however, one misses the opportunity to use it as a tool to solve some of the measurement problems that riddle the field of laboratory medicine. In this commentary I will certainly not ignore the practical problems in applying the GUM approach, but in contrast to Krouwer, I see them as challenges that need to be solved.
Because much of the discussion presented here will concern properties of measurements (and results of measurements), I find it appropriate to start by considering what a measurement actually is. A measurement is defined in the metrologic vocabulary as a set of operations having the object of determining the value of a quantity (2 ) . The value of the quantity of interest (i.e., the measurand; for example, the concentration of glucose in blood) is estimated using a measurement procedure. When further pursuing the concept of measurement, one discovers that an overwhelming part of measurement procedures in analytical chemistry, and indeed in laboratory medicine as well, involves calibration. Measurements based on calibration are, in essence, comparisons. In other words, the measurement procedure is used to compare the pa-tient sample with a calibrator that has a known value of the measurand. Thus, the origin of the value assigned to the calibrator is very important for the result of measurement. Some calibrators are prepared in-house by weighing, dissolving, and diluting to a known volume, and in these cases the value can be calculated based on knowledge about the preparation procedure. This is typically an option for substances that are readily available in high purity, e.g., glucose. More often the value of the calibrator is assigned by a measurement, in other words, by another comparison. The comparisons may continue several steps, and the chain of comparisons can have several possible endings. For example, it may end in a certified reference material, such as the NIST SRM 1951a (lipids in human serum). The values assigned to SRM 1951a have been found by a definitive method, which means that they in effect have been compared with the definition of the corresponding SI unit (the mole). Another ending could be an International Standard prepared under the auspices of WHO. The WHO International Standards have values in arbitrary units that are established in a collaborative study. Often such high-level endings do not exist, however. For example, the value of a calibrator may be assigned based on the manufacturer's best measurement procedure.
These examples of "comparison chains" illustrate the property of metrologic traceability of the result of measurement (3 ). Hence, the measurement carried out on the patient's sample is just the final one in a longer series of comparisons. Traceability is an important property of results. Almost 25 years ago, Tietz (4 ) pointed out that two results obtained by different measurement procedures at different times and different locations are comparable via their traceability to a common reference standard. In measurement, one should therefore strive for traceability to (globally) recognized standards, preferably the SI units. However, traceability alone is not enough to assure comparability. Each comparison made in the traceability chain causes uncertainty of the result. The accumulated uncertainty of the traceability chain must therefore be considered together with, or rather combined with, the uncertainty associated with the final measurement procedure.
Promises and Challenges from Traceability and Uncertainty
If measurement results are truly comparable through the means described above, there will be no need to repeat measurements when moving patients between healthcare centers, thereby reducing the inconvenience inflicted on the patients and reducing the amount of work required from the clinical laboratories. Moreover, results can-no matter the measurement procedure that has been used to obtain them-be compared with common limits and reference intervals, providing economic savings for the society. And because of the comparability of results from different measurement procedures, analytical problems such as those caused by interfering substances can be found simply by measuring the suspect sample with another measurement procedure. Any significant interference effect would cause a discrepancy between the two results that is not explained by their uncertainties.
These are some of the reasons that the idea of uncertainty should not be dismissed so lightly. But even if the concepts of metrologic traceability and uncertainty are accepted, there are difficulties in realizing them in practice. To benefit from traceability, for example, a calibration hierarchy has to be established for all clinically important measurands. Although the numbers of highlevel calibrators and reference measurement procedures are growing steadily, there is still an overwhelming number of biochemical quantities that have no high-level ending of the traceability chain (3 ). The establishment of these calibration hierarchies is a complex task, but fortunately not the primary task of routine clinical chemistry laboratories. However, when it comes to evaluation of uncertainty, the responsibility is clearly on the laboratory that produces the results. In the following, I will briefly review the GUM concept of uncertainty and in this connection respond to specific comments made in the accompanying commentary by Krouwer (1 ) . After that I will discuss two challenges that in my opinion are important to overcome. The first challenge is to make the uncertainty evaluation process more manageable, so that "routine" laboratories actually have the possibility in terms of capabilities and resources to estimate the uncertainty of the results of measurement; the second challenge is gaining access to the information about the uncertainty of calibrators supplied by external manufacturers.
Evaluation of (GUM) Uncertainty
Uncertainty (of a result of measurement) is defined in the GUM (5 ) as a parameter associated with the result of measurement, which characterizes the dispersion of values that can be reasonably attributed to the measurand. One should note from this definition that uncertainty is a property of the result of measurement, not a property of the measurement procedure. In fact, analytical imprecision is one of several components of the uncertainty. Note also that some familiar measures, for example, a SD or a confidence interval, both fulfill the criteria of the definition and that both can therefore be used to express uncertainty. However, to do arithmetic with uncertainties one needs to express the uncertainty as a SD, although the term used in the GUM is "standard uncertainty". Standard uncertainties are treated like standard deviations; in particular, their squares can be combined according to the mathematical rules for combining variances.
The principles of the uncertainty evaluation procedure are summarized schematically in Fig. 1 , and the procedure has been described in detail elsewhere (6 -8 ) . In the first step, significant sources of uncertainty (uncertainty components) are identified. Each uncertainty component is then assigned a standard uncertainty as defined above, and the standard uncertainties of all identified sources are Clinical Chemistry 49, No. 11, 2003 combined by classic "error-propagation" formulas to yield the standard uncertainty of the result of measurement. When reporting the uncertainty of the result, the combined standard uncertainty is multiplied with a socalled coverage factor, yielding an "expanded uncertainty". Usually a factor k ϭ 2 is used because of the resemblance of the expanded uncertainty to a 95% confidence interval. Higher values of k can be chosen if a higher degree of coverage is wanted. Examples of uncertainty evaluations of relevance to laboratory medicine have been worked out for the measurement of glucose in blood (9, 10 ) , calcium in serum (10 ) , and prolactin (PRL) in serum (11 ) .
GUM Uncertainty and Bias
At this point some of the specific comments by Krouwer (1 ) merit comment. One of these comments regards systematic effects and the way they should be treated according to GUM. First, according to GUM, when a significant bias has been recognized and estimated, the result of measurement should be corrected by use of this estimate, and the uncertainty of the correction included in the uncertainty of the result (5 ). Hence, GUM has only one way to treat recognized systematic effects and not three ways, as suggested by Krouwer (1 ). Krouwer bases his suggestion on an example that I will briefly present here because it shows the importance of specifying the measurement procedure, including any corrections, when talking about uncertainty. The example is a sodium measurement method with the calibrator lot as a significant systematic effect. Krouwer mentions three ways that the laboratory may behave: Laboratory 1 detects a significant bias in the calibrator lot and corrects the results. Laboratory 2 uses the uncertainty statement on the certificate from the manufacturer to estimate the uncertainty of the calibrator value. Laboratory 3 evaluates multiple calibrator lots in an experiment and uses an ANOVA model to calculate an uncertainty that can be assigned to the calibrator.
Apparently, Krouwer assumes that the systematic effect has been recognized in all three situations. In fact, however, only laboratory 1 has actually determined the bias. Hence, a correction is applied, and the uncertainty of the correction should therefore be included in the combined uncertainty of the result in accordance with the GUM approach.
In contrast, neither laboratory 2 nor laboratory 3 has estimated the bias (although the ANOVA data produced by laboratory 3 could be used in this task). They only have an uncertainty of the value of the calibrator. When making a measurement, both laboratories 2 and 3 must assume that the calibrator lot they are using is unbiased because this is the best estimate of the bias in probabilistic terms. Because they use the value of the calibrator in the measurement, the uncertainty of this value should be combined with the analytical imprecision to calculate the uncertainty of the result.
Thus, the evaluation of uncertainty depends on the actual way the result is produced. The consequences of this in terms of both the results and the accompanying uncertainty can be illustrated graphically by modeling the measurements made by laboratories 1 and 2 (laboratory 3 will produce results with a distribution similar to that of laboratory 2). The modeling parameters are presented in Table 1 . The results of the modeling are shown in Fig. 2 in terms of the distribution of 5000 measurements on a sample with a sodium concentration of 150 mmol/L. Each measurement is done with a new calibrator lot. Laboratory 2 estimates the relative standard uncertainty of a result by combining the relative standard uncertainty stated for the calibrator with the analytical imprecision:
As expected, the expanded (k ϭ 2) uncertainty around 150 mmol/L includes ϳ95% of the distribution, and a larger uncertainty interval based on k ϭ 3 includes almost all 5000 values (Fig. 2A) . Hence, the estimated uncertainty is in excellent compliance with the metrologic definition of uncertainty presented above. In contrast, a 95% confidence interval based on the analytical imprecision includes Ͻ95% of the distribution (Fig. 2A) . This means that if analytical imprecision is used to calculate a confidence interval around the result, then the "true" value of the measurand (the sodium concentration) will be outside the confidence limits more often than expected. Next consider the measurement procedure of laboratory 1. The bias of the calibrator lot can be estimated by measuring each calibrator lot multiple time, e.g., 10 times, using a reference material with higher metrologic properties than the calibrator (see Table 1 ). The relative standard uncertainty of the bias estimate is thus:
Because laboratory 1 corrects for the bias, the uncertainty of the results is a combination of uncertainty of the bias estimate and the analytical imprecision, that is:
Because of the correction applied, the distribution of the results is narrower around the value of 150 mmol/L (Fig.  2B) . However, the estimated standard uncertainty is reduced comparatively and still represents an excellent description of the values that are reasonable to attribute to the measurand. Relative analytical imprecision CV A 5% Relative standard uncertainty of the value of the calibrator (the same for all lots)
5%
Relative standard uncertainty of the value of the reference material
1%
a The values were selected purely for illustrative reasons (see Fig. 2 ). They are not representative of real sodium measurements.
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most by definition are farther away from the "true value" than 3 SD. To be sure to include outliers one could, of course, further expand the uncertainty interval by use of k Ͼ Ͼ3, but the benefit of this is hard to see. One would ultimately want to detect outliers, not to include them in abnormally large uncertainty intervals. Outliers produced by diagnostic assays have important clinical implications because they may cause the wrong diagnosis to be made and lead to wrong treatment of the patient. Several studies have demonstrated that outlying results may occur relatively frequently. Ismail et al. (12 ) , for example, investigated sets of results from 5310 patients and found analytically incorrect results for thyroid-stimulating hormone (TSH) in 28 (0.53%) cases. The lack of specificity seems to be a common reason for outlying results, and immunoassays seem to be especially prone to interferences from substances present in the patient sample but not in the calibrators (13 ). In the above-mentioned study by Ismail et al. (12 ) , interferences from unidentified substances were tested in three ways: (a) absence of parallelism on dilution with "analyte-free" sera; (b) changes in the result when analyzing the sample with heterophilic blocking agents added; or (c) differences between results when samples are analyzed by two different measurement procedures. In the latter test, a method-comparison study using patient samples without interference was used to compensate for systematic differences between the two measurement procedures. The three tests mentioned above are the standard "weapons" available to the laboratorian in the fight against interferences. However, with the patient waiting for a decision, one rarely has time to perform a method-comparison study. Checking suspect samples by use of a second measurement procedure may therefore be out of the question. However, when operating with results that are traceable to a common reference standard, and with appropriate GUM uncertainties worked out, such a checking procedure can actually work. Rapid detection of outliers is of clinical importance. The identification of measurement procedures that are susceptible to interfering substances will, in my opinion, compel manufacturers of these methods to work harder to improve them. Hence, uncertainty may in fact help to drive the improvement of the quality of such assays.
Standardization of the Uncertainty Evaluation Procedure
Although the principles of the uncertainty evaluation are easy to understand, the calculation may be difficult to carry out in practice. It takes time to evaluate uncertainty components. Moreover, the standard uncertainties are combined in different ways for different measurement methods, which adds to the complexity of the process. Krouwer (1 ) states that, ". . . ensuring that 'every effort has been made to identify such (systematic) effects' . . . is beyond the scope of most laboratories. . . ". Although I agree that evaluation of uncertainty can be demanding in terms of resources, I find Krouwer's interpretation of GUM too rigid. GUM per se does not preclude the evaluation of uncertainty of "routine" measurements. The efforts spent in evaluating the uncertainty should of course be reasonable and weighed against the purpose of the measurement and limitations in terms of time and economic resources. This is both common sense and also the usually accepted interpretation of the GUM approach in: for example, the international standard for accreditation of testing laboratories (14 ) and in the guide Quantifying Uncertainty in Analytical Measurement (15 ) . However, for the reasons mentioned, even allocating a "reasonable amount of time and effort" may not be enough. There is therefore much to gain if the uncertainty evaluation procedure can be standardized, including the systematic use of method validation data as input in the uncertainty evaluation procedure as proposed in Quantifying Uncertainty in Analytical Measurement (15 ) . The use of validation data is systematized in the so-called Model for Modular Evaluation of Uncertainty (MODUS) method (11 ) . In brief, it recognizes that a clinical chemistry measurement in general consists of a measurement procedure applied to a sample and a calibrator. This generic model is illustrated in Fig. 3 and expressed mathematically in Eq. 1. For reasons explained in my original report (11 ) , the relationship between the value of the calibrator, sampling, and analysis is expressed as a multiplicative model:
In this equation, C analysis is the (usual) result of analysis, f sampling is a correction factor for the bias introduced by the sampling process (including storage of the sample), f traceability corrects for the bias caused by systematic error in the value of the calibrator, and f other is a correction factor that corrects for bias caused by other effects not encompassed by the previous term. When the sampling is unbiased, the value assigned to the calibrator is also unbiased, and other effects do not contribute to bias, then f sampling ϭ f traceability ϭ f other ϭ 1, or in other words, the outcome of the measurement (C result ) is the same as the result of the measurement procedure, C analysis . However, this is not the case for their respective uncertainties. Assuming independence between the terms in Eq. 1, the corresponding "GUM expression" for the standard uncertainty of C result (u result ) is conveniently expressed in terms of relative standard uncertainties:
The relative standard uncertainty associated with analysis, u analysis /C analysis , can be estimated by the long-term relative analytical imprecision, CV A . If not already known to the analyst, CV A is easily accessible to experimental estimation. This uncertainty component integrates several uncertainty components associated with the analysis (e.g., dilutions, injection, analysis, and estimation of the calibration function) and therefore saves time because there is no need to evaluate each of these components individually.
The uncertainty of C result also includes contributions from f sampling (the uncertainty of sampling), from f traceability (the uncertainty of the value assigned to the calibrator, which is an element in uncertainty associated with the traceability chain), and from f other . For example, if the uncertainty from analytical drift is not included in the analytical imprecision, it should be included in the uncertainty of f other . The drawback of the simple model expressed by Eq. 1 is, of course, that there is no detailed information about the individual contributions from these components and there therefore is no basis for improving on the analysis. However, if the combined uncertainty is sufficient for the intended use of the method, this tradeoff is usually acceptable.
Analytical Assays from External Manufacturers
The presence of the factor f traceability in the MODUS model above emphasizes that traceability contributes uncertainty to the result of measurement. Information about the uncertainty of f traceability may be readily available if the calibrator is manufactured in-house, but it can be difficult to access if an external manufacturer makes the calibrator. Unfortunately, the calibrators in assays are typically delivered without a statement of uncertainty. Moreover, both the protocol for establishing traceability and the actual data are the property of the manufacturer and therefore usually not available to the laboratorian. What should one do, then? The immediate solution is to refrain from estimating the uncertainty of the traceability chain. Because genuine comparability of results is based on traceability and an appropriate uncertainty statement, ignorance about this part of the measurement is not satisfactory. Therefore, in the long run, laboratories and responsible organizations should seek to exert influence on the manufacturers to make them disclose the necessary information. In Europe, the European Union has issued the EU Directive on In Vitro Diagnostic Devices (the IVD Directive) (16 ) , which assists laboratories and their organizations in this task. The directive obliges the manufacturers of in vitro diagnostic devices to ensure traceability to a reference at a higher level in the metrologic system. Implementation of the essential requirements of the directive is supported by several international standards, including a standard on metrologic traceability of calibrators (17 ) . Because it is impossible to establish traceability without assessing the uncertainty, it is likely that the IVD Directive will increase the focus on uncertainty and therefore will lead manufacturers to share this information with their customers more often than they do at present.
What are the consequences of the traceability chain lying "hidden" at the manufacturers? Stated qualitatively, the effects include systematic differences between results obtained by different measurement procedures (different assays). Quantitative estimates of these differences can be calculated from external quality-assurance (EQA) data, where results are grouped according to the measurement procedure. As discussed in Kristiansen (11 ) , it is likely that the uncertainty associated with traceability at the manufacturer would cause a proportional effect on the results of measurement; therefore, a multiplicative model should be appropriate:
where C group i is the average of results obtained by laboratories using the measurement procedure from the ith manufacturer, is the "true" value of the measurand, the factor mf i is a constant factor that describes the relative bias associated with the measurement procedure of the ith manufacturer, and ⑀ group i is a random error caused by within-and between-laboratory variation among laboratories in the group. For the perfect assay, mf i would be equal to 1. Statistical analysis of EQA data has confirmed that the proportional model given above was valid for measurements of PRL, TSH, triiodothyronine (T 3 ), and thyroxine (T 4 ) (18 ) . Fig. 4 shows the distribution of mf i values for different measurement procedures for these four hormones.
An interesting measure is the ratio between the mf i values of two different measurement procedures, because it corresponds to the mean ratio between results obtained by these procedures. This is sometimes referred to as "the bias between the two methods", which is misleading because usually neither of the two procedures is a reference measurement procedure. The ratio between all pairs of diagnostic procedures was calculated from the data in , and values characterizing the distribution of these ratios are presented in Table 2 . For PRL, for example, the relative difference between two different "average" measurement procedures is 27% (ratio between results is 1.27), whereas the interquartile range indicates that differences between 10% and 38% are typical. For the other hormones, the average relative difference is less, ϳ10 -12%, and the corresponding interquartile range is also smaller. The results, however, indicate that relative differences up to ϳ30% are possible.
In comparison, Ismail et al. (12 ) reported an average ratio of 1.20 between TSH results obtained by the Abbot AxSYM and Bayer ACS-180, respectively. This systematic difference was found with patient samples, not EQA samples. This result is in the high end but still within the range of values found in Table 2 .
The data in Fig. 4 and Table 2 do not indicate the nature of the observed systematic differences. PRL and TSH are both polypeptide hormones, whereas T 3 and T 4 are relatively low-molecular-weight structures based on tyrosine. In spite of the different natures of the molecules, there are no large differences in the distribution of the "manufacturer effects" ( mf values) between these hormones (Fig.  4) . In comparison, different measurement procedures for cardiac troponin I may differ up to 100-fold (19 )! As mentioned, the proportional nature of the differences observed in Fig. 4 is in accordance with the suggestion (11 ) that the underlying cause is the uncertainty of the manufacturer's traceability chain. Even the large differences observed for cardiac troponin I measurement procedures seem to be at least partly attributable to differences in calibration (20 ) . It therefore seems that there indeed are some valuable perspectives in implementing the IVD Directive (16 ), thereby forcing manufacturers to focus more on traceability. It is no law of nature that different measurement procedures in clinical chemistry should differ systematically by 20%, 50%, or even more. A focus on traceability and stringent evaluation of uncertainty of measurement results may increase the pressure on manufacturers of measurement procedures to standardize their calibrators.
Conclusions
The GUM approach to uncertainty deserves closer consideration. I have tried to emphasize some of the benefits that may come from the evaluation of uncertainty, but without ignoring the challenges. In my view, focusing on traceability and uncertainty has the potential to increase pressure on manufacturers of assays so that they increase their efforts to improve the quality of their products. This drive for improvement will include both the analytical quality, i.e., the specificity of the assays, and the metrologic quality of the calibrators. In my opinion, there are no fundamental problems in applying GUM uncertainty to measurements in laboratory medicine, and the practical problems, some of them discussed above, can be solved if there is a will. However, I recognize that there are many aspects to consider, and I hope that the debate on these matters will continue. 
